117705-04-1

Basic information

• Product Name: 3-(2-oxopiperidin-1-yl)propanoic acid
• Synonyms: 3-(2-oxopiperidin-1-yl)propanoic acid;UKRORGSYN-BB BBV-182468;1-piperidinepropanoic acid, 2-oxo-;3-(2-oxopiperidin-1-yl)propanoic acid(SALTDATA: FREE);3-(2-keto-1-piperidyl)propionic acid;3-(2-oxo-1-piperidinyl)propanoic acid;3-(2-oxo-1-piperidyl)propanoic acid
• CAS NO: 117705-04-1
• Molecular Formula: C₈H₁₃NO₃
• Molecular Weight: 171.2
• Mol File: 117705-04-1.mol

Chemical Properties

• Boiling Point: 380.783°C at 760 mmHg
• Flash Point: 184.091°C
• Appearance: /
• Density: 1.199g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.504
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-(2-oxopiperidin-1-yl)propanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2-oxopiperidin-1-yl)propanoic acid(117705-04-1)
• EPA Substance Registry System: 3-(2-oxopiperidin-1-yl)propanoic acid(117705-04-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 117705-04-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
3-(2-oxopiperidin-1-yl)propanoic acid is used as a key intermediate for the synthesis of various pharmaceuticals, leveraging its chemical reactivity and structural features to facilitate the creation of biologically active molecules.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 3-(2-oxopiperidin-1-yl)propanoic acid serves as a building block for the development of new drugs, contributing to the discovery and optimization of potential therapeutic agents.
Used in Organic Compounds Synthesis:
Beyond its pharmaceutical applications, 3-(2-oxopiperidin-1-yl)propanoic acid is utilized as an intermediate in the synthesis of a range of organic compounds, highlighting its broad utility in chemical research and development.
Used in Drug Development:
3-(2-oxopiperidin-1-yl)propanoic acid is employed in drug development processes, where its unique properties can be harnessed to design and improve the efficacy of new medications, potentially leading to advancements in treatment options across various medical disciplines.

InChI:InChI=1/C8H13NO3/c10-7-3-1-2-5-9(7)6-4-8(11)12/h1-6H2,(H,11,12)

Upstream product

• 19653-33-9 ethyl piperidine-1-propionate 
• 76243-33-9 N-(3-(tetrahydropyranyloxy)propyl)valerolactam 
• 71533-22-7 1-(3'-hydroxypropyl)piperidin-2-one 
• 138196-45-9 3-(2-oxo-1-piperidinyl)propanal 
• 68634-48-0 3-[2-oxopyridin-1(2H)-yl]propanoic acid 

Downstream Products

• 77499-54-8 methyl 3-(2-oxopiperidino)propionate 
• 92577-93-0 4-[(2-carboxy-ethyl)-(toluene-4-sulfonyl)-amino]-butyric acid 
• 77191-38-9 3-(2-oxopyrrolidin-1-yl)propionic acid 
• 774605-21-9 3-(2,6-dichloro-phenyl)-5-[2-(2-oxo-piperidin-1-yl)-ethyl]-isoxazole-4-carboxylic acid ethyl ester 
• 774605-45-7 3-(2,6-dichloro-phenyl)-5-[2-(2-oxo-piperidin-1-yl)-ethyl]-isoxazole-4-carboxylic acid 
• 4386-03-2 N-carboxyethyl-γ-aminobutyric acid 

Relevant articles and documents

Supported Gold Nanoparticles for Efficient α-Oxygenation of Secondary and Tertiary Amines into Amides

Although the α-oxygenation of amines is a highly attractive method for the synthesis of amides, efficient catalysts suited to a wide range of secondary and tertiary alkyl amines using O2as the terminal oxidant have no precedent. This report describes a novel, green α-oxygenation of a wide range of linear and cyclic secondary and tertiary amines mediated by gold nanoparticles supported on alumina (Au/Al2O3). The observed catalysis was truly heterogeneous, and the catalyst could be reused. The present α-oxygenation utilizes O2as the terminal oxidant and water as the oxygen atom source of amides. The method generates water as the only theoretical by-product, which highlights the environmentally benign nature of the present reaction. Additionally, the present α-oxygenation provides a convenient method for the synthesis of18O-labeled amides using H218O as the oxygen source.

Pyrrole derivatives, their preparation and pharmaceutical compositions which contain them

This invention relates to pyrrole derivatives of formula: STR1 in which A forms with the pyrrole ring an isoindoline, 6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine, 2,3,6,7-tetrahydro-5H-[1,4]oxathiino[2,3-c]pyrrole or 2,3,6,7-tetrahydro-5H-[1,4]dithiino[2,3-c]pyrrole ring-system and Hetis naphthyridinyl, pyridyl or quinolyl which is unsubstituted or substituted with halogen, (1 to 4 C) alkyl, (1 to 4 C) alkyloxy, (1 to 4 C) alkylthio or CF3 and R=(3 to 10 C) straight- or branched-chain alkenyl or alkyl which is unsubstituted or substituted with alkyloxy, alkylthio, (3 to 6 C) cycloalkyl, NH2, alkylamino, dialkylamino, alkylcarbonylamino, (in which the amino portion is optionally substituted with alkyl), 1- or 2-piperazinyl, piperidyl, piperidino, morpholino, pyrrolidinyl, 1-azetidinyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, (1-piperazinyl)carbonyl, piperidinocarbonyl, (1-pyrrolidinyl)carbonyl, phenyl, pyridyl, 1-imidazolyl, or alternatively R=2- or 3-pyrrolidinyl, 2-, 3- or 4-piperidyl, on the understanding that the alkyl radicals are straight- or branched-chain radicals and contain, except where specifically stated, 1 to 10 C, and that the piperazinyl, piperidino, piperidyl, pyrrolidinyl and azetidinyl radicals can be unsubstituted or substituted at any position with alkyl, alkylcarbonyl, benzyl or hydroxyalkyl, or can alternatively form a lactam group with the nitrogen atom of the ring, and, where they exist, their pharmaceutically acceptable salts and optical isomers, are useful as anxiolytics.